NextCure Inc (NAS:NXTC)
$ 1.16 -0.01 (-0.85%) Market Cap: 32.49 Mil Enterprise Value: -37.15 Mil PE Ratio: 0 PB Ratio: 0.43 GF Score: 40/100

NextCure Inc at Needham Healthcare Conference Transcript

Apr 15, 2020 / 06:10PM GMT
Release Date Price: $34.88 (-8.64%)
Gil Blum
Needham & Company, LLC - Analyst

Good afternoon, everyone. It is my pleasure to introduce NextCure. NextCure is developing NC318, a Siglec-15 antibody that may be the next big thing in the field of immuno-oncology.

Timothy Mayer
NextCure, Inc. - COO

Great. Thank you, Gil. My name is Timothy Mayer and I am the Chief Operating Officer at NextCure. I would like to thank Needham for the invitation and the opportunity to present today and Gil for hosting this section.

This is our forward-looking statement. NextCure is focused on discovering and developing next-generation immunomedicines to treat cancer and other immune-related or other immune-mediated diseases by restoring normal immune function.

I would like to start by presenting our recent highlights, which are summarized in the 3 Ps: pipeline, platform and people. Our lead program, NC318, is a novel humanized monoclonal antibody that recognizes Siglec-15, or S15 as we like to call it. We will come back to this, but we presented top-line Phase 1 data at the SITC conference last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot